Acute Radiation Syndrome

Cleveland BioLabs has completed two safety trials for CBLB502 for use In Acute Radiation Syndrome or exposure to lethal radiation.

For more information, please refer to the Company’s published press releases: “Cleveland BioLabs Announces Results of Second Safety Study for CBLB502” , dated September 29, 2010 and “Cleveland BioLabs Concludes Initial Phase I Safety and Tolerability Study for CBLB502”, dated June 3, 2009, which may be found in the investors section of this website under press releases.

Acute Radiation Syndrome (ARS) occurs after individuals are exposed to high levels of ionizing radiation such as might be expected following detonation of a nuclear weapon, an improvised nuclear device, a “dirty bomb” or an accident near a nuclear power plant. The three biological systems most affected by high levels of radiation are (1) the vascular system in the brain; (2) the mucosal cells lining the gastrointestinal (GI) track and (2) the hematopoietic (HP)/immune system. Damage to the brain’s vasculature, which occurs only at the very highest levels of radiation exposure, is irreversible and lethal. GI damage, including lesions within the gut followed by sepsis, is induced by high levels of radiation. This is usually fatal within several weeks. Damage to the HP system occurs at modestly high levels of exposure and leads to failure of the immune system in fighting infections. This can be lethal within 3-6 weeks.

CBLI’s compound, CBLB502, is being investigated as a radiation countermeasure to reduce the risk of death following total body irradiation during or after radiation disaster.